$1.53
+0.02
(+1.32%)▲
1.14%
Downside
Day's Volatility :3.35%
Upside
2.24%
32.68%
Downside
52 Weeks Volatility :71.93%
Upside
58.31%
Period | Biorestorative Therapies Inc | Index (Russel 2000) |
---|---|---|
3 Months | 31.9% | 0.0% |
6 Months | 15.91% | 0.0% |
1 Year | -19.05% | 0.0% |
3 Years | -78.21% | -22.3% |
Market Capitalization | 10.7M |
Book Value | $1.56 |
Earnings Per Share (EPS) | -0.86 |
PEG Ratio | 0.0 |
Wall Street Target Price | 12.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -2770.83% |
Return On Assets TTM | -54.83% |
Return On Equity TTM | -32.65% |
Revenue TTM | 174.1K |
Revenue Per Share TTM | 0.03 |
Quarterly Revenue Growth YOY | 38.1% |
Gross Profit TTM | 119.8K |
EBITDA | -12.7M |
Diluted Eps TTM | -0.86 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.63 |
EPS Estimate Next Year | -1.68 |
EPS Estimate Current Quarter | -0.56 |
EPS Estimate Next Quarter | -0.63 |
What analysts predicted
Upside of 684.31%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 111.0K | ↑ 37.04% |
Net Income | -12.5M | ↑ 32.54% |
Net Profit Margin | -11.3K% | ↑ 382.77% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 130.0K | ↑ 17.12% |
Net Income | -14.6M | ↑ 17.02% |
Net Profit Margin | -11.3K% | ↑ 9.69% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 77.0K | ↓ 40.77% |
Net Income | -12.3M | ↓ 16.34% |
Net Profit Margin | -15.9K% | ↓ 4647.56% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 46.0K | ↓ 40.26% |
Net Income | -29.9M | ↑ 144.3% |
Net Profit Margin | -65.1K% | ↓ 49168.75% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 119.8K | ↑ 160.43% |
Net Income | -18.0M | ↓ 39.83% |
Net Profit Margin | -15.0K% | ↑ 50045.93% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 145.8K | ↑ 21.7% |
Net Income | -10.4M | ↓ 42.17% |
Net Profit Margin | -7.1K% | ↑ 7892.79% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 3.7K | ↓ 87.24% |
Net Income | -3.8M | ↓ 18.71% |
Net Profit Margin | -103.3K% | ↓ 87088.33% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 31.3K | ↑ 745.95% |
Net Income | -5.6M | ↑ 46.71% |
Net Profit Margin | -17.9K% | ↑ 85386.42% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 64.5K | ↑ 106.07% |
Net Income | -3.0M | ↓ 46.85% |
Net Profit Margin | -4.6K% | ↑ 13294.52% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 30.7K | ↓ 52.4% |
Net Income | -83.3K | ↓ 97.2% |
Net Profit Margin | -271.44% | ↑ 4349.57% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 35.0K | ↑ 14.01% |
Net Income | -2.2M | ↑ 2567.92% |
Net Profit Margin | -6.4K% | ↓ 6080.72% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 89.1K | ↑ 154.57% |
Net Income | -4.0M | ↑ 81.2% |
Net Profit Margin | -4.5K% | ↑ 1830.77% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.2M | ↓ 32.2% |
Total Liabilities | 9.8M | ↑ 14.41% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.5M | ↑ 22.97% |
Total Liabilities | 14.2M | ↑ 44.84% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 4.3M | ↑ 196.46% |
Total Liabilities | 5.7M | ↓ 60.13% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 22.5M | ↑ 416.52% |
Total Liabilities | 856.5K | ↓ 84.92% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 16.4M | ↓ 26.81% |
Total Liabilities | 602.6K | ↓ 29.64% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 12.6M | ↓ 23.26% |
Total Liabilities | 2.6M | ↑ 332.67% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 14.1M | ↓ 14.32% |
Total Liabilities | 593.9K | ↓ 1.44% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 13.3M | ↓ 5.54% |
Total Liabilities | 896.4K | ↑ 50.93% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 13.8M | ↑ 3.77% |
Total Liabilities | 975.0K | ↑ 8.77% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 18.0M | - |
Total Liabilities | 3.4M | ↑ 32.25% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 16.1M | ↓ 10.21% |
Total Liabilities | 5.3M | ↑ 54.28% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -5.1M | ↑ 32.46% |
Investing Cash Flow | -12.9K | ↑ 255.79% |
Financing Cash Flow | 4.8M | ↑ 11.83% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -6.9M | ↑ 35.54% |
Investing Cash Flow | -35.6K | ↑ 176.87% |
Financing Cash Flow | 6.8M | ↑ 42.97% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -2.0M | ↓ 71.61% |
Investing Cash Flow | -35.6K | ↑ 0.0% |
Financing Cash Flow | 5.0M | ↓ 26.49% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -3.3M | ↑ 69.52% |
Investing Cash Flow | -30.7K | ↓ 13.96% |
Financing Cash Flow | 21.3M | ↑ 324.15% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -5.9M | ↑ 76.3% |
Investing Cash Flow | -13.5M | ↑ 43866.95% |
Financing Cash Flow | 21.1M | ↓ 1.17% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.6M | ↑ 8.38% |
Investing Cash Flow | -3.3M | ↓ 66.46% |
Financing Cash Flow | 411.7K | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -2.3M | ↑ 49.28% |
Investing Cash Flow | 665.8K | ↓ 120.04% |
Financing Cash Flow | 411.7K | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -1.1M | ↓ 51.88% |
Investing Cash Flow | 665.8K | ↑ 0.0% |
Financing Cash Flow | 411.7K | ↑ 0.0% |
Sell
Neutral
Buy
Biorestorative Therapies Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Biorestorative Therapies Inc | 15.91% | 15.91% | -19.05% | -78.21% | -78.21% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Biorestorative Therapies Inc | NA | NA | 0.0 | -1.63 | -0.33 | -0.55 | NA | 1.56 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Biorestorative Therapies Inc | Buy | $10.7M | -78.21% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Biorestorative Therapies Inc
Revenue is up for the last 3 quarters, 30.7K → 89.1K (in $), with an average increase of 36.5% per quarter
Netprofit is down for the last 3 quarters, -83.33K → -4.02M (in $), with an average decrease of 1324.6% per quarter
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 56.1%
Sabby Management LLC
StoneX Group Inc
Geode Capital Management, LLC
Wealth Alliance, LLC
Renaissance Technologies Corp
Vanguard Group Inc
biorestorative therapies, inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • disc/spine program (brtxdisc™): our lead cell therapy candidate, brtx-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. we intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. the brtx-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. in an outpatient procedure, brtx-100 is to be injected by a physician into the patient’s damaged disc. the treatment is intended for patients whose pain has not been alleviated by non-invas
Organization | Biorestorative Therapies Inc |
Employees | 11 |
CEO | Mr. Lance Alstodt |
Industry | Biotechnology |
A Spac I Acquisition Corp
$1.53
+1.32%
Keyarch Acquisition Corp
$1.53
+1.32%
Connexa Sports Technologies Inc
$1.53
+1.32%
Us Value Etf
$1.53
+1.32%
First Wave Biopharma Inc
$1.53
+1.32%
Global X Msci Next Emerging
$1.53
+1.32%
Fat Projects Acquisition Corp
$1.53
+1.32%
Capital Link Global Fintech
$1.53
+1.32%
Applied Uv Inc
$1.53
+1.32%